Anavex Life Sciences Corp (AVXL)

[Amatuer17]

Here are the changes done to primary outcome

In all cases, they now have gone more positive - rather than just change - it mentions reduction - which is much aggressive as chances of failure are high

This change was made on Jul 12th

Are they too confident?

———-
Primary Outcome Measures:
1. ADAS-Cog (Alzheimer Disease Assessment Scale-Cognition)
[ Time Frame: 48 weeks ]

From - Change from baseline to week 48 in cognition according to the Alzheimer Disease Assessment Scale-Cognition (ADAS-Cog) compared to placebo


To - Reduction in cognitive decline assessed from baseline over 48 weeks with ANAVEX2-73 compared to placebo using the Alzheimer Disease Assessment Scale-Cognition (ADAS-Cog)


2. ADCS-ADL (Activities of Daily Living)
[ Time Frame: 48 weeks ]

From - Changes from baseline to week 48 in ability to perform daily activities according to the Activities of Daily Living Scale (ADCS-ADL) compared to placebo

To - Reduction in decline of the ability to perform daily activities assessed from baseline over 48 weeks with ANAVEX2-73 compared to placebo using the Activities of Daily Living Scale (ADCS-ADL)

Secondary measure

1. CDR-SB (Clinical Dementia Rating Scale Sum of Boxes)
[ Time Frame: 48 weeks ]

From - change from baseline to week 48 on Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) compared to placebo

To - Reduction in cognitive decline assessed from baseline over 48 weeks with ANAVEX2-73 compared with placebo using the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB)